How did past cancer vaccine strategies misinterpret their function?

Question

Accepted Answer

Past Cancer Vaccine Strategies Fundamentally Misunderstood Their Purpose

Previous approaches to cancer vaccines largely failed because they treated these complex biological interventions as simple drugs, overlooking their true function as agents of cellular reprogramming. Instead of developing personalised treatments that harness the immune system's specific responses, early strategies relied on a limited selection of broadly expressed, self-antigens combined with generalised adjuvants. These were then administered to patients with advanced, widespread metastatic disease, a scenario where the immune system was already compromised and the tumours had established robust mechanisms to evade immune detection.
Overreliance on Weakly Immunogenic Self-Antigens

A significant misstep in past cancer vaccine development was the selection of a small number of self-antigens. These are molecules naturally present in the body, and when overexpressed by cancer cells, they often fail to provoke a strong immune response. The immune system is trained to tolerate self-antigens to prevent autoimmune reactions. Consequently, vaccines based on these targets were weakly immunogenic, meaning they did not generate a sufficiently potent T cell response to effectively combat the cancer.
Ineffective Delivery and Immune Exclusion

The prevailing strategy involved combining these weakly immunogenic self-antigens with blunt adjuvants—substances added to vaccines to boost the immune response. However, these adjuvants lacked the sophistication to overcome the established defences of advanced cancers. Tumours at this stage often develop a phenomenon known as immune exclusion, creating a microenvironment that actively prevents T cells from infiltrating and attacking the malignant cells. Furthermore, patients with late-stage disease frequently have exhausted or depleted T cell populations, leaving them unable to mount the necessary defence even if the vaccine could reach the tumour.
Neglecting the Importance of Personalisation and Timing

Crucially, past strategies failed to appreciate the necessity of personalised T cell activation and the critical timing of intervention. The scientific consensus now clearly indicates that shared antigens are less effective than private neoantigens, which are unique mutations arising from cancer cells. By sequencing a patient's tumour and identifying these specific neoantigens, personalised vaccines can be manufactured to target the cancer more precisely. Moreover, the review highlights that attempting to vaccinate patients with bulky, end-stage disease—where the tumour microenvironment is highly immunosuppressive—is largely futile. Breakthroughs are occurring in earlier settings, such as post-surgery or pre-surgery (neoadjuvant), when the disease burden is minimal and the immune system is more capable of responding.

Reading history

Hide →

This history is cleared when the page is closed.

How did past cancer vaccine strategies misinterpret their function?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends